Drugs / JS108
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04601285 | Oct 2020 → Jun 2023 | cancer | Shanghai Junshi Bioscience Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JS108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04601285 ↗ |
| Modality | Monoclonal antibody | “recombinant humanized anti-Trop2 mAb-Tub196 conjugate” NCT04601285 ↗ |
| Route | Intravenous | “administered intravenously” NCT04601285 ↗ |